Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
UK Startups and Innovation
14NOV

Jobs plan targets the lab-skills gap

1 min read
18:53UTC

Four UK departments published a 42-page Life Sciences Jobs Plan on 9 July, targeting the lab-skills gap the biotech funding surge assumes is already solved.

TechnologyAssessed
Key takeaway

The Jobs Plan funds lab-skills training the biotech cheques assume, staffing the benches the money never mentions.

Four departments published a Life Sciences Jobs Plan on 9 July, a 42-page programme from the Department of Health and Social Care (DHSC), the Department for Science, Innovation and Technology (DSIT), the Department for Business and Trade (DBT) and the Office for Life Sciences, targeting the gap between life-sciences graduates and employer-ready laboratory skills⁠1.

The plan promises modular lab-skills training aimed at smaller firms and coordinated careers outreach. It answers a question the week's funding announcements never do: who staffs the benches.

Alchemab's Series A cheque, IMU Biosciences' June round and the wider biotech surge all assume a workforce that can run the assays, and the graduate pipeline has not kept pace with the capital. Publishing the plan the same afternoon as the Alchemab cheque was no accident of scheduling.

Deep Analysis

In plain English

Four UK government departments, the Department of Health and Social Care, the Department for Science, Innovation and Technology (DSIT), the Department for Business and Trade, and the Office for Life Sciences, jointly published a 42-page plan on 9 July. It aims to close the gap between what life-sciences graduates learn at university and the practical laboratory skills employers actually need. The plan sets out modular lab-skills training and careers outreach aimed particularly at smaller life-sciences firms, which often cannot afford to train new graduates from scratch the way larger companies can.

Deep Analysis
Root Causes

The plan targets a specific mismatch: UK life-sciences employers report graduates arrive with theoretical training but limited hands-on laboratory experience, because university lab time is expensive to scale and most degree courses cannot fund the equipment access industry roles assume on day one.

That gap sits directly upstream of raises like Alchemab's £25m cheque and IMU Biosciences' £40m round, both of which assume a pipeline of laboratory-ready staff that four government departments are only now formally trying to build.

What could happen next?
  • Meaning

    The plan is a direct policy response to a staffing gap that AI-biotech investment rounds like Alchemab's and IMU Biosciences' have been assuming is already solved.

First Reported In

Update #11 · Britain funds and defunds its own science

GOV.UK / Office for Life Sciences· 14 Jul 2026
Read original →
Different Perspectives
Association of Investment Companies (Richard Stone)
Association of Investment Companies (Richard Stone)
The trust industry body criticised the Budget for leaving Venture Capital Trust relief at 20%. It had lobbied for the 30% rate to return.
Tax Justice UK
Tax Justice UK
The campaign group opposed the 10% founders' rate as a giveaway to a small group of wealthy owners. It said the BADR cut should have gone further, to abolition.
techUK
techUK
The trade body set the new relief against the BADR cut, which halves the most a seller can save to £30,000. It says the Budget takes back with BADR part of what it gives founders.
Startup Coalition
Startup Coalition
The founder lobby group welcomed the Budget package for startups. It treats the new relief as the strongest government support for founders in years.
HM Treasury
HM Treasury
The Treasury created a 10% founders' relief on up to £10m of lifetime gains and expects about 600 people a year to use it. It says the relief rewards founders behind the UK's fastest-growing companies.
Abu Dhabi Investment Council
Abu Dhabi Investment Council
The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.